Bristol-Myers Squibb

Bristol-Myers Squibb collaborates with CytomX Therapeutics, Incyte

Wednesday, May 28, 2014 01:01 PM

Bristol-Myers Squibb has formed two separate collaboration agreements. BMS and CytomX Therapeutics are collaborating on novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody Platform. BMS and Incyte, a Wilmington, Del.-based biopharmaceutical company, have established a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of BMS’ investigational PD-1 immune checkpoint inhibitor nivolumab and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor INCB24360, in a phase I/II study.

More... »

Quest Diagnostics

Bristol-Myers Squibb, Celldex Therapeutics to collaborate

Thursday, May 15, 2014 01:24 PM

Bristol-Myers Squibb and Celldex Therapeutics have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a phase I/II study.

More... »


Bristol-Myers Squibb acquires iPierian

Wednesday, April 30, 2014 11:39 AM

Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

More... »

Trial results for AbbVie’s Hepatitis C candidate heat up race for effective treatment

Monday, April 14, 2014 12:51 PM

The race to replace interferon with a far more effective treatment for hepatitis C has become one of the most promising and lucrative battles in drug development, as AbbVie, Gilead Sciences, Merck and Bristol-Myers Squibb vie for the finish line.

More... »

Icon’s Firecrest training recognized by TransCelerate BioPharma

Monday, April 14, 2014 10:13 AM

Icon, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced that its Firecrest training meets TransCelerate BioPharma’s minimum criteria for International Conference on Harmonization Good Clinical Practice (ICH/GCP) training.

More... »

European researchers to submit proposals focused on curing virological diseases

Tuesday, April 8, 2014 02:41 PM

In a quest to cure chronic virological diseases such as HIV, hepatitis B and hepatitis C, Bristol-Myers Squibb has asked European researchers—notably junior faculty and young investigators—to submit innovative research ideas  to accelerate novel solutions as part of its Partnering for Cure program.

More... »

Five Prime Therapeutics, Bristol-Myers Squibb collaborate

Monday, March 17, 2014 01:37 PM

Five Prime Therapeutics, a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, and Bristol-Myers Squibb (BMS) have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform.

More... »

Report: pharmacovigilance market, service providers to reach $5B globally in 2019

Friday, February 28, 2014 12:02 PM

According to a new market report published by Transparency Market Research, the global pharmacovigilance market was valued at $2,147.3 million in 2012 and is estimated to reach a market worth $5,008.2 million in 2019, at a CAGR of 12.9% from 2013 to 2019.

More... »

Inovio Pharmaceuticals expands senior management team

Friday, February 21, 2014 02:38 PM

Inovio Pharmaceuticals has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointed Dr. Laurent Humeau as vice president of R&D and Dr. Jan Marie-Albert Van Tornout as vice president of Clinical Development.

More... »

Spark Therapeutics appoints Elliott Sigal to board of directors

Friday, February 14, 2014 01:27 PM

Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of debilitating diseases, has appointed Elliott Sigal, M.D., Ph.D., former director, executive vice president and chief scientific officer of Bristol-Myers Squibb, to its board of directors. Elliott led Bristol-Myers Squibb during its ascent as a biopharmaceutical leader and built one of the industry's most productive R&D organizations through his forward-thinking approach to innovation.

More... »


CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs